By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: FDA Approvs for New Blood Thinner For Knee and Hip Replacements
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Specialties > Orthopaedics > FDA Approvs for New Blood Thinner For Knee and Hip Replacements
Orthopaedics

FDA Approvs for New Blood Thinner For Knee and Hip Replacements

BarbaraDuck
BarbaraDuck
Share
3 Min Read
SHARE

The drug was not theirs though as it came from Bayer Healthcare who already markets the drug in other countries and the market name for rivaroxaban, the Bayer drug, under the J and J approval is Xarelto. Maybe this is a dumb question but one wonders why Bayer didn’t go after their own FDA approval since they already the drug distributed?  Who knows, perhaps J and J had a bigger bankroll or maybe Bayer didn’t want to spend the time and effort? 

The drug was not theirs though as it came from Bayer Healthcare who already markets the drug in other countries and the market name for rivaroxaban, the Bayer drug, under the J and J approval is Xarelto. Maybe this is a dumb question but one wonders why Bayer didn’t go after their own FDA approval since they already the drug distributed?  Who knows, perhaps J and J had a bigger bankroll or maybe Bayer didn’t want to spend the time and effort? 

I guess too with all the recalls maybe this is to be a “good will” step in the right direction?  Who knows but at least it is an alternative pill instead of an injection. Bayer already markets the drug elsewhere in the world.  There’s also Pradaxa that was approved in October of 2010 for blood thinning.

FDA Approves Pradaxa–An Alternative to Warfarin To Treat Blot Clots Associated With Atrial Fibrillation

WASHINGTON – Johnson & Johnson said Friday that U.S. regulators have approved its new type of blood thinner shown to reduce deadly blood clots in patients who have undergone knee and hip replacements.

The Food and Drug Administration decision makes rivaroxaban the first U.S.-approved drug that works by blocking a clotting protein called factor Xa. That’s in contrast to older blood thinners that work by preventing platelets from sticking together.

The once-a-day pill will serve as an alternative to the popular injection Lovenox, which is the standard treatment for patients who have undergone orthopedic surgery. The drugs had similar results in head-to-head trials, including similar rates of side effects such as major internal bleeding. J&J said its new drug would be priced similarly to Lovenox, which is marketed by French drugmaker Sanofi-Aventis SA.

Rivaroxaban was discovered by German drugmaker Bayer Healthcare, which already markets the drug in 110 countries around the world. New Brunswick, N.J.-based J&J will market the drug in the U.S. under the brand name Xarelto.

J&J wins U.S. approval for new blood thinner – USATODAY.com

More Read

FDA’s Agenda for 2016: Biggest Issues on Agency’s Calendar for the New Year
Time to Talk About Constipation
The Thanksgiving Z-pack
Statins Benefits Extend Beyond the Heart
30 Years Ago All These Baby Boomers Would Have Been in Wheel Chairs

 

TAGGED:FDAorthopaedicspharmaceuticals
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

Epidemiological Health Benefits
Personal and Epidemiological Health Benefits of Blood Pressure Management
Health
October 13, 2025
Traumatic Brain Injuries
Understanding Traumatic Brain Injuries: What Families Need to Know
Policy & Law
October 10, 2025
Remote Monitoring touchpoints
Remote Monitoring Touchpoints Patients Will Actually Follow
Technology
October 9, 2025
dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025

You Might also Like

Costs Associated with Spinal Disorders and Treatment

July 6, 2011

mHealth: Regulation vs. Innovation

June 28, 2012

The $78 Pill

October 10, 2012
OrthopaedicsSpecialties

Selecting The Perfect Physiotherapist To Treat Chronic Complications

March 6, 2020
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?